retatrutide phase 2 results weight loss Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a trial Effects of once-weekly subcutaneous retatrutide

246253, Legro, Richard S., et al

These dual agonists could simultaneously exert the functions of GLP-1 and other incretins such as glucagon [219, 220], gastric inhibitory polypeptide (GIP) [221] and gastrin [222], enabling better anti-diabetes efficacy

This means the medication continues protecting your blood sugar and metabolic health even when weight loss has stalled

However, it might be covered by some plans and with prior authorization

Accurate dosage calculations depend on peptide concentration and dilution methods when working with research compounds

DRM reports receiving research support from Janssen, serving on advisory boards and as a consultant for Novo Nordisk, Novartis, Eli Lilly, Sanofi-Aventis, Janssen and Servier, and giving lectures for Novo Nordisk, Servier, Sanofi-Aventis, Eli Lilly, Novartis and Janssen